Health
Rapid generation of divergent synthetic antibodies against SARS-CoV-2 in a cell-free engineering platform – News-Medical.Net
In a groundbreaking bioRxiv paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute…
In a groundbreaking bioRxiv* paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute in the US engineered antibodies against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein by using a novel approach. In doing so, they also identified more than 800 predicted binder families.
The ongoing coronavirus disease (COVID-19) pandemic is caused by the SARS-CoV-2,…
-
Business20 hours agoThe pros and cons of buying CBA shares in September
-
Noosa News20 hours agoRent changes on way for hundreds of social housing recipients following government review
-
Business16 hours agoWhere will Berkshire Hathaway be in 1 year?
-
Noosa News19 hours agoPolice reject claims about detained protester; SEQ train lines to be disrupted; BlueCare to cut enrolled nurses